

MELANOMA

S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma.

<https://clinicaltrials.gov/ct2/show/NCT02196181?term=S1320&rank=1>

